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Several lines of evidence have placed the catechol-O-methyltransferase (COMT) gene in the limelight as a candidate
gene for schizophrenia. One of these is its biochemical function in metabolism of catecholamine neurotransmitters;
another is the microdeletion, on chromosome 22q11, that includes the COMT gene and causes velocardiofacial
syndrome, a syndrome associated with a high rate of psychosis, particularly schizophrenia. The interest in the
COMT gene as a candidate risk factor for schizophrenia has led to numerous linkage and association analyses.
These, however, have failed to produce any conclusive result. Here we report an efficient approach to gene discovery.
The approach consists of (i) a large sample size—to our knowledge, the present study is the largest case-control
study performed to date in schizophrenia; (ii) the use of Ashkenazi Jews, a well defined homogeneous population;
and (iii) a stepwise procedure in which several single nucleotide polymorphisms (SNPs) are scanned in DNA pools,
followed by individual genotyping and haplotype analysis of the relevant SNPs. We found a highly significant
association between schizophrenia and a COMT haplotype ( ). The approach presented can be58Pp 9.5 # 10
widely implemented for the genetic dissection of other common diseases.
Introduction
Schizophrenia (MIM 181500) is a common psychiatric
disease that affects ∼1% of the world population. Since
genetic and molecular factors have not been identified,
schizophrenia is diagnosed by phenotypic symptoms only.
Schizophrenia, like most psychiatric disorders, is a com-
plex disease that cannot be explained by a single genetic
or environmental factor (McGuffin et al. 1995). Although
many monogenic disease genes have been cloned, this has
not been the case for genes that increase risk for complex
diseases, including schizophrenia. Linkage studies have
provided suggestive evidence for many schizophrenia-sus-
ceptibility loci, including some on chromosome 22, but
there has been little success in the replication of these
findings (Pulver 2000). Association studies, mainly with
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candidate genes, have also not provided any consistent
result.
Velocardiofacial syndrome (VCFS [MIM 192430]) is
associated with a microdeletion on chromosome 22q11.
Patients with VCFS have a high risk of developing psy-
chiatric diseases, especially schizophrenia. Some studies
of patients with VCFS have found that 20%–30% of
them developed schizophrenia (Murphy et al. 1999). In
addition, patients with schizophrenia have an increased
rate of the 22q11 microdeletion, compared with the
general population (Karayiorgou et al. 1995; Usiskin et
al. 1999). These findings suggest that the 1.5–3-Mb
22q11 deletion region contains one or more genes that
contribute to schizophrenia risk.
The catechol-O-methyltransferase (COMT [MIM
116790]) gene, which is located in the 22q11 microde-
letion, is a candidate gene for schizophrenia that has been
studied extensively. COMT is one of the enzymes that
degrade catecholamines, including dopamine (Axelrod
and Tomchick 1958). The biological functions of COMT,
in addition to the gene’s location in the microdeletion,
make it an attractive candidate gene for schizophrenia.
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A nonsynonymous SNP at codon 108/158 in the COMT
gene generates a valine-to-methionine (Val/Met) substi-
tution and apparently influences the enzyme’s activity
(Lachman et al. 1996). However, association studies on
the Val/Met polymorphism have failed to produce any
conclusive results. Recently, the Val allele was shown to
be associated with cognitive characteristics that are pres-
ent in schizophrenia—namely, poor performance in tests
of working memory and inefficiency of information pro-
cessing in the prefrontal cortex (Egan et al. 2001).
In light of the inconclusive genetic evidence, we
tested the possible association of COMT with schizo-
phrenia, by applying a more powerful approach. We
tested several SNPs and haplotypes in the COMT gene
on a very large sample of an Israeli Ashkenazi Jewish
population. The use of the Ashkenazi Jewish founder
population has several advantages (Shifman and Dar-
vasi 2001; Zak et al. 2001), primarily in reducing ge-




A research group of psychiatrists from seven medical
centers in Israel collected samples and data from their
hospitalized patients. All diagnoses were assigned by a
standard procedure. This procedure included a direct in-
terview using the structured clinical interview for person-
ality disorders (SCID), a questionnaire with inclusion and
exclusion criteria and cross-references to medical records.
The inclusion criteria specified that subjects had to be
diagnosed with one of the schizophrenia subtypes defined
by the Diagnostic and Statistical Manual of Mental Dis-
orders (DSM-IV), that all four grandparents of each sub-
ject were of Ashkenazi Jewish ethnic origin, and that each
subject or the subject’s legal representative has signed the
informed-consent form. The exclusion criteria excluded
subjects diagnosed with at least one of the following dis-
orders: psychotic disorder due to a general medical con-
dition, substance-induced psychotic disorder, mood dis-
order with psychotic features, schizoaffective disorder,
schizophreniform disorder, schizotypal disorder, schizoid
disorder, and paranoid personality disorder. Correspond-
ing institutional review boards and the National Genetic
Committee of the Ministry of Health approved the stud-
ies. Samples from healthy Ashkenazi individuals were col-
lected from volunteers in blood banks. Samples fromAsh-
kenazi patients with other diseases, which served as
additional controls in the present study, were also col-
lected in Israel under standards similar to those used for
the patients with schizophrenia.
Genotyping Assay
Genomic DNA was prepared from blood samples
through use of the Nucleon kit (Pharmacia). DNA was
diluted to 100 ng/ml, according to optical-density mea-
surements. Pools were created with equal aliquots of
each sample. For the amplification of the DNA fragment
containing each SNP, one biotinylated and one unmod-
ified primer were designed, using Primer3 (Primer3Web
site), to give an average product of 150 bp. HotStar Taq
polymerase (Qiagen) was used in 45 amplification cycles
of PCR (20 s at 94C, 30 s at 55C, and 30 s at 72C).
Genotyping was performed by the Pyrosequencing assay,
using an internal primer designed by the Pyrosequencing
program and the commercial kit, according to the man-
ufacturer’s standard protocol. Results of the pooled
DNA samples were analyzed by the Pyrosequencing al-
lele-frequency quantification software.
Statistical Analysis
To measure linkage disequilibrium (LD) between
SNPs, we estimated the haplotype frequencies through
use of the expectation-maximization algorithm on 70
individual genotypes and calculated Lewontin’s D′ and
the Pearson correlation (Devlin and Risch 1995; Slatkin
and Excoffier 1996). Association between markers and
schizophrenia risk was tested by comparing genotype
and allele frequencies in patients and control individuals,
using a standard x2 test under a normal approximation.
We tested for differences across all possible haplotype
frequencies through use of a likelihood-ratio statistic
that was calculated from the estimated haplotype-fre-
quency likelihoods (Zhao et al. 2000; Fallin et al. 2001).
We calculated the overall significance across male and
female 2#2 tables by means of the Cochran-Mantel-
Haenszel test, and we estimated the common odds ratio
(OR) by means of the Mantel-Haenszel estimator.
Population attributable risk (PAR) was calculated for
the tested diplotypes as , where ,(K 1)/K Kp  f # gi i
fi is the frequency of the i genotype, and gi is the estimated
genotype relative risk of the i genotype (Khoury et al.
1993). The number of affected sib pairs required to detect
linkage to the COMT gene was estimated according to
the model of Risch and Merikangas (1996) and using the
rs737865-rs165599 haplotype and amultiplicativemodel
with genotypic relative risks of g and g2 for the AG-AG
and GG-GG genotypes, respectively.
Results
Estimation of Allele Frequencies in DNA Pools and LD
between SNPs
To test the COMT-schizophrenia association, we ex-
amined 12 SNPs in the COMT gene (fig. 1). These SNPs,
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Figure 1 Location of SNPs studied in the COMT locus and allele-frequency differences observed between patients with schizophrenia
and control individuals by means of analysis of the DNA pools. Four SNPs were not polymorphic (NP), and one amplification failed (F). Three
of the SNPs studied (rs6270, rs6267, and rs165688) cause a nonsynonymous change.
chosen from the public databases (dbSNP Home Page),
included all nonsynonymous SNPs, including the well-
studied Val/Met polymorphism, rs165688. The 12 SNPs
were initially examined by employing DNA pooling. In
this process, equal amounts of DNA from hundreds of
individuals are mixed together, and the allele frequency
is estimated from the relative signals of the alleles in the
genotyping assay. For every SNP, we compared the allele
frequencies in a total of seven replicated pools comprised
of ∼300 schizophrenia and 1,000 control DNA samples,
using the quantitative Pyrosequencing technology. In-
dividual genotyping of several known pools indicates
that allele frequencies in the DNA pools are accurately
estimated (Wasson et al. 2002).
Of the 12 SNPs studied, 4 were found not to be poly-
morphic in the population we studied, and an additional
SNP failed to undergo PCR amplification. Among the
remaining seven SNPs, we found significant allele-fre-
quency differences between patients and control indi-
viduals for five SNPs (see fig. 1). Upon individual ge-
notyping of 70 individuals chosen randomly for each of
these SNPs, we found SNPs rs6269 and rs4633 to be in
complete LD ( ) with SNP rs165688. Therefore,′D p 1
SNPs rs165688 (encoding the Val/Met polymorphism),
rs165599 (near the 3′ UTR), and rs737865 (near exon
#1) were selected for large-scale individual genotyping.
Genetic Association with Schizophrenia by Individual
Genotyping
We initially genotyped the well-studied Val/Met poly-
morphism (SNP rs165688) in 720 patients with schizo-
phrenia and 2,970 control individuals (table 1). A mod-
est association was found between SNP rs165688 and
schizophrenia in men, with the highest significance for
the Val/Val (G/G) genotype ( ; ;Pp .0074 ORp 1.35
95% CI 1.08–1.67). Although women did not show an
effect, the difference between the effect in men and that
in women was not significant ( ).Pp .07
SNP rs165599 was next genotyped in 724 patientswith
schizophrenia and 4,014 control samples (table 1). Sur-
prisingly, we found significant differences in allele and
genotype frequencies between men and women among
the healthy control individuals (A allele frequency p
65.4% in women vs. 61.3% in men; ). WePp .00089
retested this interesting result by genotyping an indepen-
dent control sample set of 532 male and 353 female in-
dividuals with five different diseases (insulin-dependent
diabetes mellitus, non–insulin-dependent diabetes melli-
tus, prostate cancer, asthma, and colon cancer;∼180 sam-
ples for each disease). Essentially the sameallele-frequency
difference between men and women was observed in this
additional control group (A allele frequencyp 64.9% in
women vs. 59.4% in men; ). Overall, the allelePp .020
difference between men and women is highly significant
( ).5Pp 9.0# 10
In light of the results presented above, case and control
individuals were matched for gender in all analyses. The
effect of SNP rs165599 was found to be highly significant
in women, both at the allele level (G allele predisposing,
) and at the genotype level, with the G/6Pp 9.1# 10
G genotype displaying the greatest significance (Pp
; ; 95% CI 1.52–2.97). Men66.8# 10 ORp 2.13
showed a smaller effect in the same direction (Pp .10
for the G allele and for the G/G genotype). ThePp .09
difference between the G/G genotype effect in men and
women was significant ( ).Pp .01
Lastly, SNP rs737865 was analyzed in 714 patients
with schizophrenia and 2,849 control individuals. SNP
rs737865 was found to be significantly associated with
schizophrenia in men ( ) and women (Pp .0011 Pp
). Male patients with schizophrenia displayed an ex-.012
cess of the G/G genotype ( ; ;4Pp 2.3# 10 ORp 1.58
95% CI 1.24–2.02), whereas female patients showed an
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SAMPLE SIZE G G/G A/G A/A Pa
Control Patient Control Patient Control Patient Control Patient Control Patient Genotype Allele G/G
rs165688:
F 706 262 50.8 53.4 25.9 26.3 49.7 54.2 24.4 19.5 .25 .30 .90
M 2,264 458 52.1 55.8 25.8 31.9 52.6 47.8 21.6 20.3 .027 .041 .0074
All .041 .024 .023
rs165599:
F 1,380 263 34.7 44.9 11.7 22.1 45.9 45.6 42.3 32.3 .000010 .0000091 .0000068
M 3,519 461 39.0 41.8 14.8 17.8 48.4 47.9 36.8 34.3 .20 .10 .090
All .000030 .000088 .000072
rs737865:
F 685 250 38.7 45.0 15.5 17.6 46.4 54.8 38.1 27.6 .012 .014 .43b
M 2,164 464 40.9 45.6 15.8 22.8 50.2 45.5 34.0 31.7 .0011 .0083 .00023
All .00016 .00036 .00048
a P values are provided for testing genotype, allele, and G/G versus A/G  A/A frequencies in the patients against those in the control
individuals.
b In women, a stronger P value was obtained when testing A/G and G/G versus A/A ( ).Pp .0029
excess of A/G and G/G ( ; ; 95%Pp .0029 ORp 1.61
CI 1.18–2.22). Although the allele frequencies in male
and female patients with schizophrenia were similar, the
genotype distribution was significantly different between
the sexes ( ).Pp .052
Haplotype Analyses
We tested the haplotype-frequency differences between
the patients with schizophrenia and control individuals.
We analyzed the three combinations of two-SNP haplo-
types, as well as the three-SNP haplotype (table 2). When
we compared the overall frequency differences across all
possible haplotypes, the rs737865-rs165599 haplotype
gave the most significant overall association with schizo-
phrenia ( ). Since the G allele in the three4Pp 1.42# 10
SNPs was found to be associated with schizophrenia, we
specifically tested the association of G-G or G-G-G hap-
lotypes in the four combinations (table 2). The G-G-G
haplotype gave the most significant association with
schizophrenia ( ; ; 95% CI8Pp 9.5# 10 ORp 1.46
1.36–1.57). Although the G-G haplotype of SNPs
rs737865 and rs165599 gave a lower significance (Pp
; ; 95% CI 1.32–1.51), the effect79.6# 10 ORp 1.41
of this haplotype is not significantly different from that
of the G-G-G haplotype.
PAR and the Power of Association
Although “risk” genes for common diseases are ex-
pected to be of weak effect, they may correspond to a
high PAR, because of their high allele frequency. The
female PAR calculated for the joint genotype of SNPs
rs165599 and rs737865 is 32.2%, and the male risk is
13.5%. Thus, 32.2% of female patients with schizo-
phrenia and 13.5% of male patients would not have
been affected if the population were monomorphic for
the protective alleles of the two SNPs. If the causative
alleles are not in complete LD with the haplotype ana-
lyzed, then the PARs calculated here are lower limits for
the true effect of the gene.
Association studies have been shown to be more pow-
erful than linkage studies in the identification of disease
alleles with small genetic effect (Risch and Merikangas
1996). We calculated the number of affected sib pairs
that would have been required in order to identify the
COMT gene as a schizophrenia-risk gene by means of
linkage analysis. The genotypic relative risk for the
rs737865-rs165599 haplotype is for womengp 1.65
and for men. Thus, the number of affected sibgp 1.31
pairs that would have been required is 16,000–190,000,
depending on the sex ratio among the samples.
Discussion
The Involvement of the Val/Met Polymorphism
in Schizophrenia Susceptibility
Using 12 SNPs distributed in the 27 kb of the COMT
gene and testing 7 of them with a very large sample of
Ashkenazi Jews, we have been able to confirm a complex
association between the COMT gene and schizophrenia.
In addition, the data also suggest that SNP rs165688
itself, encoding the Val/Met polymorphism, has only a
modest or no effect on schizophrenia risk, which ex-
plains the repeated failure by previous investigators to
consistently associate COMT with schizophrenia. The
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Male Female All r D′Patient Control Patient Control
rs737865-rs165599: .0093 .0014 .00014 .30 .32
G-A 18.53 17.84 17.08 18.96
G-G 28.30 23.12 28.74 19.67 .0015 .000055 .00000096
A-A 38.90 43.50 38.43 45.30
A-G 14.27 15.55 15.76 16.06
rs737865-rs165688: .017 .046 .0057 .68 .85
G-A 3.20 3.12 3.04 2.19
G-G 43.61 37.71 42.98 36.85 .0016 .021 .000092
A-A 40.30 44.59 42.76 46.32
A-G 12.88 14.58 11.22 14.64
rs165599-rs165688: .096 .0012 .0011 .44 .58
G-A 6.73 7.69 10.49 7.74
G-G 34.97 30.69 34.35 27.28 .011 .0024 .00013
A-A 37.48 40.22 36.07 41.47
A-G 20.81 21.40 19.08 23.51
rs165688-rs737865-rs165599: .0084 .0069 .00045
G-G-A 15.77 15.83 14.80 17.87
G-G-G 27.84 21.90 28.18 19.01 .00023 .000047 .000000095
G-A-A 5.56 5.74 4.49 5.64
G-A-G 7.33 8.82 6.74 9.14
A-G-A 2.94 1.96 2.05 1.60
A-G-G .26 1.15 .99 .54
A-A-A 33.33 38.07 34.20 38.95
A-A-G 6.97 6.54 8.56 7.23
a r p Pearson correlation; D′ p standardized LD coefficient.
modest effect occasionally observed at the Val/Met poly-
morphism is most probably due to the correlation be-
tween this SNP and SNP rs737865, which does have a
significant effect on susceptibility to schizophrenia. This
is implied by the higher OR of SNP rs737865 (ORp
for rs737865 vs. 1.35 for rs165688) and by the1.58
high degree of LD between the two SNPs ( ;′D p 0.85
see table 2). Our results also suggest the possibility of
more than one functional polymorphism affecting sus-
ceptibility to schizophrenia at the COMT locus. This is
supported by the finding that SNP rs165599 affects pri-
marily women, whereas rs737865 affects both sexes,
although in different ways.
Sex-Specific Susceptibility to Schizophrenia
We report two conceptually different results for SNP
rs165599—that is, (i) the allele difference between men
and women in the general population and (ii) the highly
significant association of this polymorphismwith schizo-
phrenia. Each of these two observations is striking on
its own. Although it is not within the scope of the current
work, a connection between the two findings should be
studied further. For example, one may hypothesize that
the two findings are related, in that the G allele, which
increases the risk of schizophrenia in women, may also
reduce viability of a female fetus. Transmission ratio
distortion (TRD) among offspring of different sexes has
been reported in mice and humans (Naumova and Sap-
ienza 1994; Naumova et al. 1998; Shendure et al. 1998;
Herrmann et al. 1999; Silva et al. 1999). In mice, le-
thality of male embryos and meiotic drive influenced by
the sex chromosomes has been reported as a mechanism
of offspring sex-specific TRD (de la Casa-Esperon et al.
2000; Pardo-Manuel de Villena et al. 2000). For hu-
mans, this represents, to our knowledge, the first highly
significant, replicated result of its kind.
Our findings are suggestive of a sex-specific genetic
component in schizophrenia. Sex-specific genetic effects
have not been reported elsewhere for this disorder. For
example, a large twin study failed to find evidence of
sex-specific genetic effects for schizophrenia (Cannon et
al. 1998), perhaps reflecting the low statistical power of
that approach. Sex differences in the schizophrenic phe-
notype itself have been described elsewhere (Salem and
Kring 1998). A sex-specific genetic component has been
demonstrated in obsessive-compulsive disorder (OCD),
in which the low-activity COMT allele (Met/Met ge-
notype) is associated with the disease in male patients
only (Karayiorgou et al. 1997). The sex-specific phe-
notypic differences observed in patients with schizo-
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phrenia may reflect partial sex-based distinctions in the
etiology of the disease, and these may be related to dif-
ferences in COMT activity. In this regard, it has been
shown that women generally have 20%–30% lower
COMT activity levels than men (Boudikova et al. 1990),
and COMT-knockout mice display sex differences in
phenotype (Gogos et al. 1998).
We may speculate that a candidate for the connection
between COMT and sex-specific phenotypic differences
is estrogen (Salem and Kring 1998), which downregu-
lates COMT transcription (Xie et al. 1999). Accordingly,
both symptom exacerbation (Salem andKring 1998) and
COMT activity in schizophrenic women have been ob-
served to parallel blood estrogen levels (Parvez et al.
1978). Finally, female patients with OCD display the
converse picture as compared with patients with schizo-
phrenia, with respect to the effects of estrogen (Casas et
al. 1986; Neziroglu et al. 1992).
Optimal Study Design
In the present study, we have established a stepwise
process that can be widely applied to test candidate genes
and even to conduct full genome scans for the identifi-
cation of the genetic basis of complex traits. The process
consists of (i) examining a significant number of SNPs
per gene and estimating allele frequencies in case versus
control individuals, through use of DNA pools, which
will ensure that either the functional SNPs, or at least
some SNPs that are in LD with the functional poly-
morphisms are selected; (ii) establishing LD patterns, to
select an informative subset of SNPs for further individ-
ual genotyping; (iii) performing individual genotyping
in a large sample set with the selected SNPs (large sam-
ples are necessary, since one may expect more than one
functional polymorphism—or, as shown here, a sex ef-
fect that may effectively reduce sample size); and (iv)
analyzing haplotypes, to extract the maximum statistical
power that the data can provide.
In addition to the stepwise procedure described above,
the use of a well-characterized homogeneous population,
like Ashkenazi Jews (Wijsman 1984; Motulsky 1995;
Escamilla 2001; Ostrer 2001), also contributed to the
unprecedented level of statistical significance achieved in
the present study. The use of homogeneous populations
increases gene effect and reduces the chance of false pos-
itives due to population stratification. False positiveswill
arise when case and control individuals are not perfectly
matched and when the SNPs studied display population
allele-frequency differences, as is the case for the Val/
Met polymorphism, which displays population allele-
frequency differences within and between geographic ar-
eas (Palmatier et al. 1999).
Our results strongly associate the COMT gene and
schizophrenia, but the possibility that an additional
gene in this region confers susceptibility to the disease
cannot be excluded. Nonetheless, the combination of
previous functional evidence presented for COMT in
the context of schizophrenia (Weinberger et al. 2001)
and the discoveries elaborated in the present study cer-
tainly point toward COMT as a susceptibility gene for
schizophrenia.
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